Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation…
By M. Cavo, P. Tacchetti, F. Patriarca, M. Petrucci, L. Pantani, M. Galli, F. Di Raimondo, C. Crippa, E. Zamagni, A. Palumbo and 11 more. The Lancet, 2010
821 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/d50c9182b56fc152841bfd3cf276489b4d37f536
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
In Oncology
Citations in the corpus
- Revised International Staging System for Multiple Myeloma: a report from IMWG (2015, neutral): “Age, years 2,872 (65) 2,080 (68) 65 1,573 (35) 980 (32) 65 Sex Male 2,393 (54) 1,652 (54) Female 2,050 (46) 1,408 (46) Missing 2 — HR-CA by iFISH No 2,718 (61) 2,337 (76) Yes 851 (19) 723 (24) Missing 876 (20) — ISS stage I 1,615 (36) 1,171 (38) II 1,630 (37) 1,174 (38) III 987 (22) 715 (24) Missing”
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016, background): “New primary malignant tumor‡‖ 17 (5) NA NA 14 (4) NA NA”
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma (2012, neutral): “Thalidomide–glucocorticoids without bortezomib 65 72 137 (30)”